Cargando…

Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies

PURPOSE: We investigated the treatment outcomes of immune checkpoint inhibitor (ICI) rechallenge in patients with recurrent gynecologic cancers. MATERIALS AND METHODS: We retrospectively reviewed the medical records of 20 patients who underwent rechallenge with PD-1 inhibitors for recurrent gynecolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Migang, Chang, Chi-Son, Choi, Min Chul, Lee, Jeong-Won, Park, Hyun, Joo, Won Duk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522879/ https://www.ncbi.nlm.nih.gov/pubmed/37727917 http://dx.doi.org/10.3349/ymj.2023.0063

Ejemplares similares

Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
por: Choi, Min Chul, et al.
Publicado: (2020)

Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge
por: Park, Benjamin C, et al.
Publicado: (2022)

Machine Learning for Recurrence Prediction of Gynecologic Cancers Using Lynch Syndrome-Related Screening Markers
por: Kim, Byung Wook, et al.
Publicado: (2021)

Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib
por: Lee, Min Kyung, et al.
Publicado: (2015)

Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers
por: Noh, Joseph J., et al.
Publicado: (2022)

Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study
por: Yang, Jin, et al.
Publicado: (2022)

RECOVERY AND RECHALLENGE AFTER THE NEUROLEPTIC MALIGNANT SYNOROME
por: Chopra, Mohit P., et al.
Publicado: (2001)

Synchronous gynecologic malignancy and preliminary results of Lynch syndrome
por: Kim, Min Kyu, et al.
Publicado: (2011)

Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge
por: van der Westhuizen, Andre, et al.
Publicado: (2022)

Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review
por: Kitagawa, Shingo, et al.
Publicado: (2020)

Non-Recurrence of Carbamazepine Induced Vitiligo after Rechallenge with Carbamazepine
por: Saeedloo, Masoomeh, et al.
Publicado: (2013)

Bell's palsy during rechallenge of immune checkpoint inhibitor
por: Takemura, Kohji, et al.
Publicado: (2023)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
por: Kaira, Kyoichi, et al.
Publicado: (2021)

The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies
por: Marinelli, Oliviero, et al.
Publicado: (2019)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy
por: Grosso, Federica, et al.
Publicado: (2018)

Acute generalized exanthematous pustulosis caused by iopamidol with recurrence on rechallenge with iopromide
por: Mizuta, Takahiro, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

Rechallenge in Immune Checkpoint Inhibitors Associated Renal Tubular Acidosis
por: Shah, Chintan V., et al.
Publicado: (2023)

Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
por: Myrdal, Caitlyn N., et al.
Publicado: (2020)

Identification of Lynch Syndrome in Patients with Endometrial Cancer Based on a Germline Next Generation Sequencing Multigene Panel Test
por: Kim, Yoo-Na, et al.
Publicado: (2022)

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
por: Reinbolt, Raquel E., et al.
Publicado: (2013)

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
por: Kooshkaki, Omid, et al.
Publicado: (2020)

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events
por: Fujisaki, Toshiya, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2022)

Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement
por: Suh, Dong Hoon, et al.
Publicado: (2018)

Current Status in Rechallenge of Immunotherapy
por: Hu, Han, et al.
Publicado: (2023)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

A Rare Case of Recurrent Myoid Hamartoma Mimicking Malignancy: Imaging Appearances
por: Ko, Myung-Su, et al.
Publicado: (2010)

Successful clozapine rechallenge following recurrent clozapine-associated pancreatitis: a case report
por: Rodriguez, Victoria, et al.
Publicado: (2020)

The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
por: Perdyan, Adrian, et al.
Publicado: (2023)

Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer
por: Lee, Yoo-Young, et al.
Publicado: (2019)

Rechallenge of lamotrigine after development of rash
por: Houser, Jennifer, et al.
Publicado: (2018)

Lithium rechallenge after renal transplant
por: Beasley, Anna K., et al.
Publicado: (2018)

5-Fluorouracil Rechallenge After Cardiotoxicity
por: Desai, Aakash, et al.
Publicado: (2020)

Pelvic exenteration for recurrent or advanced gynecologic malignancies – Analysis of outcome and complications
por: ter Glane, L., et al.
Publicado: (2021)

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
por: Minchom, Anna, et al.
Publicado: (2020)

Recurrence of methotrexate-induced leukoencephalopathy after methotrexate rechallenge: A case report and literature review
por: AlKawi, Ammar, et al.
Publicado: (2022)

Research Progress on Structure and Anti-Gynecological Malignant Tumor of Shikonin
por: Ke, Li-Na, et al.
Publicado: (2022)

Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7tqjp2fjjaudnk6ifa2b7ahp35